Tardive Dyskinesia
45
5
6
27
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Published Results
11 trials with published results (24%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
4.4%
2 terminated out of 45 trials
93.1%
+6.6% vs benchmark
38%
17 trials in Phase 3/4
41%
11 of 27 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 27 completed trials
Clinical Trials (45)
Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia
Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD
Xenazine in Late Dyskinetic Syndrome With Neuroleptics
Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine
ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders
Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects
Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets
Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes
A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects
Studying Patterns in Patient Engagement Among Tardive Dyskinesia Patients
Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia
Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia
Reducing Involuntary Movements in Participants With Tardive Dyskinesia
Aim to Reduce Movements in Tardive Dyskinesia